Sichuan Cancer Hospital & Institute — Chengdu, Sichuan

Public research footprint of Sichuan Cancer Hospital & Institute, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Stopped or withdrawn

Most-studied conditions

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma · Perioperative Treatment in Subjects With Locally Advanced Resectable… · Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer · Breast Cancer

Recently updated registry entries

NCT07294872 — A Study of TIL in Advanced Solid Tumors (CZ) (Not Yet Recruiting)
NCT07726342 — SMP-656 for HER2-Positive Advanced Breast Cancer (Not Yet Recruiting)
NCT05152147 — A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in… (Active Not Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Sichuan Cancer Hospital & Institute?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 07, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.